Leading Cardiac MRI Analysis developers parner to enhance user experience in global distribution

Jan. 22, 2013 - PRLog -- Medis medical imaging systems BV, and Diagnosoft, Inc. USA announce an agreement to package Diagnosoft’s patented and FDA cleared HARP® technology for regional analysis and quantification with the widely used QMass MR Enterprise solution.   The world’s largest cardiac MRI analysis  software client base and future customers can now benefit from the unique and exceptional solutions developed by both organizations.

Johan (Hans) HC Reiber, PhD, CEO, Medis stated: ” Diagnosoft is the world’s innovator and leader in MR strain analysis. We welcome their solution, allowing Medis to expand its CMR application portfolio offered to the global research and clinical community.”

Dr. Nael Osman, Co-Founder and CEO of Diagnosoft, stated: “This partnership represents the joining of two organizations steeped in product innovation and commitment to the advancement of the cardiac MRI modality.  Researchers, clinicians, and cardiac patients across the globe will benefit from this relationship.”

About Medis medical imaging systems

Medis medical imaging systems bv is a leading provider of innovative quantification software solutions that enable clinicians, technicians and researchers to accurately quantify medical images. The company offers software solutions for a range of modalities (MRI, MSCT, X-ray angiography and intravascular imaging) and for the medical specialties of cardiology and radiology. Medis’ global headquarters are in Leiden, the Netherlands, and the company has a subsidiary in Raleigh, NC, USA.

About Diagnosoft, Inc.

Diagnosoft® provides innovative software analysis tools focused on both research and clinical healthcare. Since 2007, the company has provided leading edge solutions to analyze and quantify cardiac magnetic resonance images.  Diagnosoft is well known for developing HARP®, the only FDA 510k-cleared software for tagged MR images, which has been an essential component in over 180 publications advancing cardiovascular research.